0.7886
-0.0013 (-0.16%)
-0.0013 (-0.16%)
Upgrade to Real-Time
Market Closed
Volume | 1,274,398 |
|
|||||
News | (2) | ||||||
Day High | 0.7998 | Low High |
|||||
Day Low | 0.74 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.78 | 0.74 | 0.7998 | 0.7886 | 0.7899 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
451 | 1,274,398 | $ 0.763596 | $ 973,125 | - | 0.2311 - 2.54 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:59:54 | 1,300 | $ 0.7886 | USD |
CytoDyn Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 638.77M | 810.01M | 453.49M | $ - | $ - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
50.35M | $ - | - | - | - |
CytoDyn (QB) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.816 | 0.88 | 0.7035 | 0.8182642 | 2,221,627 | -0.0274 | -3.36% |
1 Month | 0.445 | 1.30 | 0.43 | 0.8545361 | 4,844,669 | 0.3436 | 77.21% |
3 Months | 0.3209 | 1.30 | 0.31 | 0.6855805 | 2,737,165 | 0.4677 | 145.75% |
6 Months | 0.60 | 1.30 | 0.2311 | 0.5325765 | 2,510,867 | 0.1886 | 31.43% |
1 Year | 1.37 | 2.54 | 0.2311 | 0.8438018 | 2,642,661 | -0.5814 | -42.44% |
3 Years | 0.4299 | 10.01 | 0.2311 | 2.74 | 3,686,653 | 0.3587 | 83.44% |
5 Years | 0.70 | 10.01 | 0.0552 | 2.62 | 2,345,862 | 0.0886 | 12.66% |
CytoDyn (QB) Description
CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |